CCR7 Antibody

中文名稱：

CCR7兔多克隆抗體
貨號：

CSB-PA004846LA01HU
規(guī)格：

￥440
圖片：
Immunohistochemistry analysis of human lung tissue using CSB-PA004846LA01HU at dilution of 1:100

Immunocytochemistry analysis of human tonsil tissue using CSB-PA004846LA01HU at dilution of 1:100

Immunofluorescent analysis of Hela cells using CSB-PA004846LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) CCR7 Polyclonal antibody
Uniprot No.：

P32248
基因名：

CCR7
別名：

CCR7; CMKBR7; EBI1; EVI1; C-C chemokine receptor type 7; C-C CKR-7; CC-CKR-7; CCR-7; BLR2; CDw197; Epstein-Barr virus-induced G-protein coupled receptor 1; EBV-induced G-protein coupled receptor 1; MIP-3 beta receptor; CD antigen CD197
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human C-C chemokine receptor type 7 protein (332-378AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，CCR7 Antibody (CSB-PA004846LA01HU)，的標(biāo)記方式是Non-conjugated。對于CCR7 Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA004846LB01HU	CCR7 Antibody, HRP conjugated	ELISA
FITC	CSB-PA004846LC01HU	CCR7 Antibody, FITC conjugated
Biotin	CSB-PA004846LD01HU	CCR7 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點(diǎn)詳情

功能：

Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions.
基因功能參考文獻(xiàn)：
1. Results suggest that chemokine (C-C motif) receptor 7 (CCR7)promotes triple-negative breast cancer (TNBC) metastasis and may serve as a target for breast cancer diagnosis and treatment. PMID: 30032244
2. High CCR7 expression is associated with urinary bladder cancer metastasis. PMID: 28534984
3. these data indicate CCL19/CCR7 contributes to proliferation and invasion of ESCs, which are conducive to the pathogenesis of endometriosis through activating PI3K/Akt pathway PMID: 28856757
4. The research findings demonstrate for the first time that the chemokines CCL19, CCL21 and CCR7 play important roles in bone destruction by increasing osteoclast migration and resorption activity, and that has been linked to rheumatoid arthritis pathogenesis. PMID: 28729639
5. CXCR4, CCR7, VEGF-C and VEGF-D expression might have synergistic effects on the lymph node metastasis in patients with cervical cancer. PMID: 28535405
6. the acute GvHD (aGvHD) patients received higher percentage of CD4+CCR7+ T-cells in donor T-cells, whereas chronic GvHD (cGvHD) patients were transplanted with higher percentages of CD8+CCR7+ T-cells. Functional experiments demonstrated that CCR7+ T-cells exhibited higher potential for activation than CCR7- T-cells did. PMID: 28112745
7. these results demonstrated that CCL21/CCR7 may activate EMT in lung cancer cells via the ERK1/2 signaling pathway. PMID: 28487957
8. CCL21/CCR7 interaction was shown to allow NK cell adhesion to endothelial cells (ECs) and its reduction by hypoxia. PMID: 28416768
9. Study shows that miR-1275 can positively regulate CCR7 expression in squamous cell carcinoma of head and neck (SCCHN) with different mechanisms. PMID: 29278769
10. Study provide evidence that CCR7 mediates EMT progress via AKT pathway, which indicates that CCR7 has a key role in breast cancer progression. PMID: 28378417
11. Report an increased percentage of peripheral CCR7 T cells accompanied by endothelial dysfunction in patients with ankylosing spondylitis. PMID: 28421995
12. The analysis of gene amplification and mRNA levels showed the expression of CCR7 in breast cancer correlated with better prognosis. PMID: 28930757
13. that CCR7 mediates TGF-beta1-induced MMP2/9 expression through NF-kappaB signaling PMID: 28817313
14. leukocyte subsets express distinct patterns of CCR7 sialylation that contribute to receptor signaling and fine-tuning chemotactic responses. PMID: 26819318
15. tumor microenvironment stimulation down-regulated the migration of CCR7-expressing tumor cells toward CCL21 and inhibited the formation of directional protrusions toward CCL21 in a novel 3-dimensional hydrogel system. PMID: 26936935
16. CCR7 expression levels in human tumors correlate with signatures of CD141(+) DC, intratumoral T cells, and better clinical outcomes. PMID: 27424807
17. specific role for CCL21/CCR7 in promoting EMT and metastasis in CD133+ pancreatic cancer stem-like cells PMID: 27505247
18. This study showed that CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients. PMID: 26616645
19. High tumoral CCR7 expression correlated with potential lymphatic involvement and poor prognosis of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. PMID: 28114889
20. Results show that upregulation of CCR7 promotes cell proliferation and inflammation in A549 non-small cell lung cancer cells. However, silencing of CCR7 via siRNA treatment promotes cell apoptosis and suppresses the inflammatory response and TGF-beta1-induced EMT, which may be associated with NF-kappaB signaling. PMID: 28339080
21. Down-regulating CCR7 expression in MG63 cells could apparently inhibit cell proliferation, migration and invasion abilities of MG63 cells, and also induce cell apoptosis. PMID: 27916085
22. These results suggest that upregulation of rat CCR7 expression does not change the phenotype, differentiation, or proliferation capacity of human adipose-derived stem cells (hASCs), but does enable efficient migration of hASCs to rat secondary lymphoid organs. PMID: 28035134
23. CCL21/CCR7 interaction contributes to the time-dependent proliferation of PTC cells by upregulating cyclin A, cyclin B1 and cyclin-dependent kinase 1 (CDK1) expression via the extracellular signal-regulated kinase (ERK) pathway associated with iodine. PMID: 27574129
24. we conclude that CCR7 gene locus harbours a polymorphism that modifies risk of MI in patients with Coronary artery disease (CAD). Replication of this association could be sought in a prospective cohort of initially healthy individuals PMID: 27317472
25. this study shows that plasmacytoid dendritic cells from rheumatoid arthritis patients have high expression levels of CCR7 PMID: 27421624
26. This study suggests that NRP1 expression and LVD are independent factors that are likely to predict the risk of LN metastasis in squamous cell carcinoma (SCC)of the tongue, whereas the expression of VEGFC, VEGFR3, CCR7, and SEMA3E are nonindependent predictive factors PMID: 27666723
27. High CCR7 expression is associated with gastric cancer. PMID: 26984468
28. CCR7 pathway up-regulates Twist expression via ERK and PI3K/AKT signaling to manage the epithelial-mesenchymal transition of pancreatic ductal adenocarcinoma PMID: 26219899
29. Constitutively expressed Siglec-9 inhibits LPS-induced CCR7, but enhances IL-4-induced CD200R expression in human macrophages. PMID: 26923638
30. High CXCR4 expression in primary breast tumors (PTs) was found to be associated with luminal A type tumor, suggesting more favorable outcome. In contrast, CCR7 and FOXP3 expressions in PTs represented luminal B tumors, pointing to more aggressive tumor behavior. Maspin expression did not differ between luminal types. PMID: 28011488
31. Results indicated that CCR7 is overexpressed in gallbladder cancer tissues and its expression correlates with staging and lymph node metastasis. PMID: 27009073
32. CCL21/CCR7 induce VEGF-D up-regulation and promote lymphangiogenesis via ERK/Akt pathway in lung cancer. PMID: 26884842
33. The present study demonstrated that down-regulation of CCR7 reduced proliferation, cell cycle, cell migration and invasion in prostate cancer cells PMID: 26722441
34. Our findings suggested that MUC1 plays an important role in CCL21-CCR7-induced lymphatic metastasis and may serve as a therapeutic target in esophageal squamous cell carcinoma . PMID: 26667143
35. Membrane associated PGES1dependent release of PGE2 is ccompanied by elevated CCR7 expression in colon cancer cells. PMID: 26352871
36. Pyk2 is a key downstream signaling molecules of CCR7 in SCCHN, which promotes SCCHN tumorigenesis and progression. PMID: 26352169
37. the CCR7 axis mediates TGF-beta1-induced EMT via crosstalk with NF-kappaB signaling, facilitating lymph node metastasis and poorer overall survival in patients with gastric cancer PMID: 26176983
38. Blockade of CCR7, or treatment with a p38 MAP kinase inhibitor, reduced lymphatic dissemination of epithelial-mesenchymal transition cells. PMID: 25961925
39. findings indicated that circulating memory Tfh cells, especially CCR7+ICOS+ memory Tfh cells, may be associated with the relapse of MS and may serve as a new therapeutic target PMID: 26231034
40. The chemotactic interaction between CCR7 and its ligand, CCL21, may be a critical event during progression in pancreatic cancer PMID: 21594558
41. CrkL regulates CCL19 and CCR7-induced epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinoma patients. PMID: 25636509
42. Recycling accounts, to a major extent, for the high levels of surface CXCR4/CCR7 on CLL cells. Increased CCR4/CCR7 is detectable not only in circulating leukemic cells, but also in secondary lymphoid organs of CLL patients with lymphoadenopathy. PMID: 26282174
43. in given donor/recipient pairs, KIR2DS4 expression may contribute to potentiating natural killer cell function by increasing both the cytotoxicity and the expression of CCR7 on their surface. PMID: 25961063
44. Data indicate that inhibition of TGF-beta-activated protein kinase 1 (TAK1) reduces chemokine (C-C motif) receptor 7 (CCR7) expression. PMID: 25557171
45. CCL21/CCR7 pathway activates signallings to up-regulate Slug pathway, leading to the occurrence of epithelial-mesenchymal transition process in human chondrosarcoma PMID: 25556164
46. our study suggested that CCR7 promotes Snail expression to induce the epithelial-mesenchymal transition, resulting in cell cycle progression, migration, and invasion in gastric cancer PMID: 25572817
47. High CCR7 expression was associated with colorectal cancer metastasis. PMID: 26179425
48. The solution structure of CCL19 is reported. It contains a canonical chemokine domain. Chemical shift mapping shows the N-termini of PSGL-1 and CCR7 have overlapping binding sites for CCL19 and binding is competitive. PMID: 26115234
49. These results reveal that CCR7 and VEGF-C display a significant crosstalk and suggest a novel role of the CCL21/CCR7 chemokine axis in the promotion of breast cancer-induced lymphangiogenesis. PMID: 25744065
50. High expression of CCR-7 is associated with atherosclerotic arteries. PMID: 25318003
顯示更多

收起更多
亞細(xì)胞定位：

Cell membrane; Multi-pass membrane protein.
蛋白家族：

G-protein coupled receptor 1 family
組織特異性：

Expressed in various lymphoid tissues and activated B- and T-lymphocytes, strongly up-regulated in B-cells infected with Epstein-Barr virus and T-cells infected with herpesvirus 6 or 7.
數(shù)據(jù)庫鏈接：

HGNC: 1608

OMIM: 600242

KEGG: hsa:1236

STRING: 9606.ENSP00000246657

UniGene: Hs.370036

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human